Late-breaking abstract at ERS Congress provides new estimate from
leading researchers and key opinion leaders
PARIS--(BUSINESS WIRE)--
Roughly 175 million Europeans have obstructive sleep apnoea, according
to a late-breaking abstract presented by ResMed today at the European
Respiratory Society’s annual ERS Congress in Paris. Leading researchers
estimate 90 million Europeans have moderate to severe sleep apnoea,
meaning they experience at least 15 breathing events an hour during
sleep.
These statistics are based on the latest scoring rules for determining
one’s apnoea–hypopnoea index (AASM 2012) and are connected with a
16-country study announced in May 2018 that revealed an estimated 936
million people worldwide have sleep apnoea, a chronic
sleep-disordered breathing condition associated with increased risk of
mortality and reduced quality of life.
The new global prevalence is nearly tenfold higher than the previous one
– 100 million – estimated by the World Health Organization in 2007.
European countries with the highest prevalence are:
-
Russia, 40 million
-
Germany, 26 million
-
France, 24 million
-
Ukraine, 13 million
-
Spain, 9 million
-
United Kingdom, 8 million
“This data is a warning call to Europe’s doctors and other care
providers to properly identify, screen and diagnose these people so they
can get the life-changing treatment they need,” said Dr. Adam
Benjafield, lead researcher and ResMed’s vice president of Medical
Affairs.
Benjafield said one sign of an at-risk patient is whether they have a
related chronic medical condition:
-
83% of people with drug-resistant hypertension have sleep apnoea
-
77% of people with obesity
-
76% of people with chronic heart failure
-
72% of people with type 2 diabetes
-
62% of people with a prior stroke
-
49% of people with atrial fibrillation
“Doctors should screen their patients if they have any of these
conditions,” said Benjafield, “especially if a patient has exhibited
sleep apnoea-related symptoms like snoring, daytime sleepiness or
frequent nighttime urination.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company
with more than 5 million cloud-connected devices for daily remote
patient monitoring, changes lives with every breath. Its award-winning
devices and software solutions help treat and manage sleep apnoea,
chronic obstructive pulmonary disease and other respiratory conditions.
Its 6,000-member team strives to improve patients’ quality of life,
reduce the impact of chronic disease and save healthcare costs in more
than 120 countries. ResMed.com
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180918005278/en/
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For
investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
Source: ResMed